CLVLF.US Clinuvel Pharmaceuticals Ltd

Healthcare Biotechnology USA Stocks
4.95 USD
Close of Nov 13, 2026
4.95 8.40
Market cap
USD 250M
P/E
11.0x
P/B
1.33x
ROE
34.4%
Dividend yield
0.72%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.

Is CLVLF.US undervalued?

Graham number
Price4.95
Graham value6.13
Discount19.3%

CLVLF.US trades 19.3% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Clinuvel Pharmaceuticals Ltd fundamental analysis

No fundamental analysis for Clinuvel Pharmaceuticals Ltd yet.

Clinuvel Pharmaceuticals Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Clinuvel Pharmaceuticals Ltd

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimu…

Full company profile